Bluebird bio (NASDAQ:BLUE)
initiated with Buy rating and $120 (56% upside) price target at Bank of
America. Upgraded to Outperform with a $100 price target at Evercore
ISI. Shares up 2% premarket.
Centene (NYSE:CNC) initiated with Outperform rating and $90 (43% upside) price target at Evercore ISI. Shares up 1% premarket.
Myovant Sciences (NYSE:MYOV) initiated with Neutral rating and $15 (18% upside) price target at Citigroup.
Merit Medical Systems (NASDAQ:MMSI) upgraded to Outperform with a $43 (18% upside) price target at Raymond James. Shares up 2% premarket.
CRISPR Therapeutics (NASDAQ:CRSP) downgraded to In Line with a $52 (flat) price target at Evercore ISI. Shares down 3% premarket.
Eyenovia (NASDAQ:EYEN) downgraded to Market Perform at Oppenheimer. Shares down 3% premarket.
ResMed (NYSE:RMD) downgraded to Neutral with a $174 (9% upside) price target at UBS.
https://seekingalpha.com/news/3537231-bluebird-up-2-premarket-on-two-new-bullish-calls
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.